US · Healthcare · Health Information Services
EPS came in at -0.26 against a street estimate of -0.15 — a miss of 73.3%.
Analysts rate Sophia Genetics SA a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $9.75.
| Fund | Stake |
|---|---|
| Generation Investment Management LLP | 7.98% |
| AIGH Capital Management, LLC | 4.64% |
| Akre Capital Management, LLC | 4.37% |
| Royce & Associates, LP | 3.97% |
| Principal Financial Group Inc | 2.78% |
| Ameriprise Financial Inc | 2.60% |
| Banque Pictet & Cie SA | 2.59% |
| Awm Investment Company Inc | 2.00% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue was $23.310 million, up 27% from $18.323 million in Q2 2025. • Gross profit was $15.061 million, up 23%; gross ma | 2026-08-04 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • SOPHiA GENETICS SA has agreed to sell 10,526,000 ordinary shares to underwriters at a purchase price of $4.465 per share. • Under | 2026-06-22 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • Share capital is CHF 4,466,061, divided into 89,321,220 fully paid registered shares with a par value of CHF 0.05 each. • The com | 2026-06-22 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • The filing is a Form 6-K submitted by SOPHiA GENETICS SA for June 2026. • The company’s SEC Commission File Number is 001-40627. | 2026-06-04 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Annual report covers the fiscal year ended December 31, 2025. • The company had 68,486,338 ordinary shares outstanding as of the | 2026-03-03 |
| Annual report FY2024 (20-F) | 2025-03-04 |
| Annual report FY2023 (20-F) | 2024-03-05 |
| Annual report FY2022 (20-F) | 2023-03-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sophia Genetics SA — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.